KIF26A

Across TCGA pan-cancer cohorts, KIF26A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KIF26A data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher KIF26A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIF26A expression acts as an unfavorable survival marker.

SCLC, LUAD, and ESCA are the cancer types where KIF26A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.233	0.657	.005	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	12	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	DFS	Median	IV	0.156	0.669	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KIF26A–SCLC (OS)

Open the SCLC breakdown →